Opendata, web and dolomites

NO-GO SIGNED

NO-GO: UNVEILING THE POWER OF C-08 FOR THE TREATMENT OF OVER ACTIVE BLADDER

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NO-GO project word cloud

Explore the words cloud of the NO-GO project. It provides you a very rough idea of what is the project "NO-GO" about.

validated    profits    validation    minimizing    sustainable    doctors    america    symptoms    multiple    opportunity    capacity    clinical    create    interactions    launched    standards    worldwide    fine    safety    urgency    expensive    health    natural    extend    business    internalize    iso    trial    natura    ecosystem    psychological    2021    gt    cultivating    21    vivo    save    relaxing    bodies    patients    population    characterization    over    landscape    market    icelandic    bladder    life    angelica    saga    2005    seize    dropout    selling    pharmacological    108    urinary    regulate    75    claims    80    leaves    depression    jobs    day    starting    drugs    performed    age    plant    effect    mass    north    impaired    anxiety    prescription    sagapro    recommend    iceland    nocturia    gmp    people    precursor    healthcare    preserving    archangelica    syndrome    16    active    complying    oab    vitro    10    normal    million    expansion    improvement    obtain    demonstrating    rates    small    tune    clinically    too    efficiency    prepared    social    efsa    benefit    30    roi    formulation    embarrassment    prevalence    treatments    made    500    66   

Project "NO-GO" data sheet

The following table provides information about the project.

Coordinator
SAGANATURA EHF 

Organization address
address: SUDURHELLU 8
city: HAFNARFJORDUR
postcode: 221
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Iceland [IS]
 Total cost 2˙232˙470 €
 EC max contribution 1˙562˙729 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SAGANATURA EHF IS (HAFNARFJORDUR) coordinator 1˙562˙729.00

Map

 Project objective

Over Active Bladder (OAB) is a syndrome characterized by several urinary symptoms, like urgency and nocturia. Prevalence is >10% of the population, 500 million people worldwide, and increases with age (>30% over 75 years old). OAB has psychological consequences such as embarrassment, impaired social interactions, depression and anxiety. Current pharmacological treatments for OAB are associated with multiple side effects and 80% dropout rates within 1 year. At Saga Natura we have developed NO-GO, a natural product for improving OAB symptoms, made from the leaves of the Icelandic plant Angelica archangelica. NO-GO’s precursor SagaPro was launched on the market in 2005, becoming Iceland’s top-selling non-prescription urinary product. We have performed in vivo and in vitro characterization of SagaPro’s bladder relaxing effect and we have clinically validated SagaPro in a small-scale clinical trial on 66 OAB patients, demonstrating it’s efficiency and safety. In Phase 2 we want to fine-tune our formulation, increase and internalize our production capacity complying with ISO and GMP standards and extend our clinical validation. We will also regulate NO-GO through the EFSA to obtain health claims. This way we will be prepared for our product’s mass expansion in Europe and in North America starting in 2021. This project will create 21 new jobs and profits of €108 Million with ROI of 16.6 after 5 years on the market. End-users will benefit from improvement of symptoms, no side effects, and ability to lead a normal every day life. Doctors will be able to recommend NO-GO to their OAB patients, a product with no side effects, and healthcare bodies will save costs on expensive OAB prescription drugs with too high dropout rates. Finally, with our sustainable approach for cultivating Angelica archangelica we will seize this business opportunity while also preserving the Icelandic landscape, using natural resources and minimizing the impact to the ecosystem.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NO-GO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NO-GO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

CyreenApplication (2019)

Connecting Ad-Impressions with Purchase. The new advanced Advertisement at the point of sales.

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More